U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Polysomy 17

MedGen UID:
269464
•Concept ID:
C1514214
•
Cell or Molecular Dysfunction

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVPolysomy 17

Recent clinical studies

Etiology

FISH and HER2/neu equivocal immunohistochemistry in breast carcinoma.
Patil Okaly GV, Panwar D, Lingappa KB, Kumari P, Anand A, Kumar P, Chikkalingaiah MH, Kumar RV
Indian J Cancer 2019 Apr-Jun;56(2):119-123. doi: 10.4103/ijc.IJC_333_18. PMID: 31062729
HER2 and TOP2A Gene Amplification and Protein Expression in Upper Tract Urothelial Carcinomas.
Aumayr K, Klatte T, Neudert B, Birner P, Shariat S, Schmidinger M, Susani M, Haitel A
Pathol Oncol Res 2018 Jul;24(3):575-581. Epub 2017 Jul 28 doi: 10.1007/s12253-017-0260-0. PMID: 28755093
Impact of polysomy 17 on HER2 testing of invasive breast cancer patients.
Liu Y, Ma L, Liu D, Yang Z, Yang C, Hu Z, Chen W, Yang Z, Chen S, Zhang Z
Int J Clin Exp Pathol 2014;7(1):163-73. Epub 2013 Dec 15 PMID: 24427336Free PMC Article
Status of HER2 amplification, polysomy 17 and histopathological features of 425 Pakistani breast cancer patients.
Moatter T, Aban M, Iqbal W, Azam I, Pervaiz A, Siddiqui F, Murad F, Pervez S
Asian Pac J Cancer Prev 2011;12(11):3069-73. PMID: 22393991
Genetic alterations and protein expression of HER2 and chromosome 17 polysomy in breast cancer.
Zhu X, Lu Y, Lu H, Yang W, Tu X, Cai X, Zhou X
Hum Pathol 2011 Oct;42(10):1499-504. Epub 2011 Jun 14 doi: 10.1016/j.humpath.2010.04.023. PMID: 21676436

Diagnosis

FISH and HER2/neu equivocal immunohistochemistry in breast carcinoma.
Patil Okaly GV, Panwar D, Lingappa KB, Kumari P, Anand A, Kumar P, Chikkalingaiah MH, Kumar RV
Indian J Cancer 2019 Apr-Jun;56(2):119-123. doi: 10.4103/ijc.IJC_333_18. PMID: 31062729
Role of Genomic Alterations in HER2 Positive Breast Carcinoma: Focus on Susceptibility and Trastuzumab-therapy.
Singla H, Kalra S, Kheterpal P, Kumar V, Munshi A
Curr Cancer Drug Targets 2017;17(4):344-356. doi: 10.2174/1568009616666161216094026. PMID: 27993117
HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity.
Hanna WM, Rüschoff J, Bilous M, Coudry RA, Dowsett M, Osamura RY, Penault-Llorca F, van de Vijver M, Viale G
Mod Pathol 2014 Jan;27(1):4-18. Epub 2013 Jun 28 doi: 10.1038/modpathol.2013.103. PMID: 23807776
Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma.
Yoon HH, Shi Q, Sukov WR, Lewis MA, Sattler CA, Wiktor AE, Wu TT, Diasio RB, Jenkins RB, Sinicrope FA
J Clin Oncol 2012 Nov 10;30(32):3932-8. Epub 2012 Sep 17 doi: 10.1200/JCO.2012.43.1890. PMID: 22987085Free PMC Article
Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17.
Simonetti S, Russo R, Ciancia G, Altieri V, De Rosa G, Insabato L
Int J Surg Pathol 2009 Jun;17(3):198-205. doi: 10.1177/1066896909333415. PMID: 19443884

Therapy

Monosomy 17 in potentially curable HER2-amplified breast cancer: prognostic and predictive impact.
Page DB, Wen H, Brogi E, Dure D, Ross D, Spinelli KJ, Patil S, Norton L, Hudis C, McArthur HL
Breast Cancer Res Treat 2018 Jan;167(2):547-554. Epub 2017 Oct 6 doi: 10.1007/s10549-017-4520-1. PMID: 28986743Free PMC Article
Role of Genomic Alterations in HER2 Positive Breast Carcinoma: Focus on Susceptibility and Trastuzumab-therapy.
Singla H, Kalra S, Kheterpal P, Kumar V, Munshi A
Curr Cancer Drug Targets 2017;17(4):344-356. doi: 10.2174/1568009616666161216094026. PMID: 27993117
HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity.
Hanna WM, Rüschoff J, Bilous M, Coudry RA, Dowsett M, Osamura RY, Penault-Llorca F, van de Vijver M, Viale G
Mod Pathol 2014 Jan;27(1):4-18. Epub 2013 Jun 28 doi: 10.1038/modpathol.2013.103. PMID: 23807776
Status of HER2 amplification, polysomy 17 and histopathological features of 425 Pakistani breast cancer patients.
Moatter T, Aban M, Iqbal W, Azam I, Pervaiz A, Siddiqui F, Murad F, Pervez S
Asian Pac J Cancer Prev 2011;12(11):3069-73. PMID: 22393991
The important molecular markers on chromosome 17 and their clinical impact in breast cancer.
Zhang W, Yu Y
Int J Mol Sci 2011;12(9):5672-83. Epub 2011 Sep 5 doi: 10.3390/ijms12095672. PMID: 22016618Free PMC Article

Prognosis

HER2 and TOP2A Gene Amplification and Protein Expression in Upper Tract Urothelial Carcinomas.
Aumayr K, Klatte T, Neudert B, Birner P, Shariat S, Schmidinger M, Susani M, Haitel A
Pathol Oncol Res 2018 Jul;24(3):575-581. Epub 2017 Jul 28 doi: 10.1007/s12253-017-0260-0. PMID: 28755093
HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity.
Hanna WM, Rüschoff J, Bilous M, Coudry RA, Dowsett M, Osamura RY, Penault-Llorca F, van de Vijver M, Viale G
Mod Pathol 2014 Jan;27(1):4-18. Epub 2013 Jun 28 doi: 10.1038/modpathol.2013.103. PMID: 23807776
Chromosome 17 polysomy: correlation with histological parameters and HER2NEU gene amplification.
Orsaria M, Khelifa S, Buza N, Kamath A, Hui P
J Clin Pathol 2013 Dec;66(12):1070-5. Epub 2013 Aug 1 doi: 10.1136/jclinpath-2013-201506. PMID: 23908451
Status of HER2 amplification, polysomy 17 and histopathological features of 425 Pakistani breast cancer patients.
Moatter T, Aban M, Iqbal W, Azam I, Pervaiz A, Siddiqui F, Murad F, Pervez S
Asian Pac J Cancer Prev 2011;12(11):3069-73. PMID: 22393991
Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response.
Reinholz MM, Bruzek AK, Visscher DW, Lingle WL, Schroeder MJ, Perez EA, Jenkins RB
Lancet Oncol 2009 Mar;10(3):267-77. doi: 10.1016/S1470-2045(09)70063-4. PMID: 19261255Free PMC Article

Clinical prediction guides

The frequency and clinical significance of centromere enumeration probe 17 alterations in human epidermal growth factor receptor 2 immunohistochemistry-equivocal invasive breast cancer.
Katayama A, Starczynski J, Toss MS, Shaaban AM, Provenzano E, Quinn CM, Callagy G, Purdie CA, Millican-Slater R, Purnell D, Chagla L, Oyama T, Pinder SE, Chan S, Ellis I, Lee AHS, Rakha EA
Histopathology 2022 Oct;81(4):511-519. Epub 2022 Aug 8 doi: 10.1111/his.14728. PMID: 35879836Free PMC Article
HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity.
Hanna WM, Rüschoff J, Bilous M, Coudry RA, Dowsett M, Osamura RY, Penault-Llorca F, van de Vijver M, Viale G
Mod Pathol 2014 Jan;27(1):4-18. Epub 2013 Jun 28 doi: 10.1038/modpathol.2013.103. PMID: 23807776
Chromosome 17 polysomy: correlation with histological parameters and HER2NEU gene amplification.
Orsaria M, Khelifa S, Buza N, Kamath A, Hui P
J Clin Pathol 2013 Dec;66(12):1070-5. Epub 2013 Aug 1 doi: 10.1136/jclinpath-2013-201506. PMID: 23908451
Status of HER2 amplification, polysomy 17 and histopathological features of 425 Pakistani breast cancer patients.
Moatter T, Aban M, Iqbal W, Azam I, Pervaiz A, Siddiqui F, Murad F, Pervez S
Asian Pac J Cancer Prev 2011;12(11):3069-73. PMID: 22393991
Genetic alterations and protein expression of HER2 and chromosome 17 polysomy in breast cancer.
Zhu X, Lu Y, Lu H, Yang W, Tu X, Cai X, Zhou X
Hum Pathol 2011 Oct;42(10):1499-504. Epub 2011 Jun 14 doi: 10.1016/j.humpath.2010.04.023. PMID: 21676436

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...